XHKG
8307
Market cap6mUSD
Oct 07, Last price
0.13HKD
1D
-2.94%
1Q
16.81%
Jan 2017
-85.00%
IPO
-95.86%
Name
Medicskin Holdings Ltd
Chart & performance
P/E
55.95
P/S
1.09
EPS
0.00
Div yield, %
—
Shrs. gr., 5y
-1.19%
Rev. gr., 5y
2.79%
Revenues
48m
+6.13%
Net income
936k
P
CFO
6m
-36.38%
Dividend
Jul 05, 20210.025 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medicskin Holdings Limited, an investment holding company, provides medical skin care services in Hong Kong. The company operates Medicskin centers, which provides various medical skin care services for the treatment of skin diseases and problems, such as acne, pigmentation, rosacea, dermatitis, eczema, and warts, as well as improvement of appearance through inter alia, skin rejuvenation, facial sculpturing, and body contouring treatments; and treatment of acne scars and enlarged pores, removal of undesirable naevi, and hair removal. It provides medical consultancy services. In addition, the company engages in the sale of skincare products and medical skincare services. Further, it provides prevention healthcare services; body care and men care services, as well as offer mediskin vaccination. Medicskin Holdings Limited was founded in 2000 and is headquartered in Sheung Wan, Hong Kong. The company is a subsidiary of Topline Worldwide Limited.
Key people
Kwok Leung Kong
Executive Chairman of the Board, Chief Executive Officer · since 2018
Chung Wai Kong
Executive Director and Legal and Compliance Officer · since 2014
Chief Financial Officer, Executive Director, Company Secretary · since 2017
Kan Tsui
Vice President, Executive Director · since 2018
Betty Suet Ling Sze
Head of business and product development · since 2013
Non-Executive Independent Director · since 2014
Siu Cheung Leung
Non-Executive Independent Director · since 2014
Sze On Lui
Non-Executive Independent Director · since 2023
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||